Drugs / neopeptide-loaded dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07609901 | Oct 2026 → Oct 2032 expected | Lynch syndrome | Radboud University Medical Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | neopeptide-loaded dendritic cells | “A phase III, multicentre, randomised, double-blind, placebo-controlled trial evaluating disease-free survival after vaccination with with neopeptide-loaded dendritic cells or...” NCT07609901 ↗ |
| Modality | Cell therapy | “vaccination with neopeptide-loaded dendritic cells” NCT07609901 ↗ |
| Route | Other | “injections intranodally” NCT07609901 ↗ |